Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Nash P., COATES LC., Fleishaker D., Kivitz AJ., Mease PJ., Gladman DD., FitzGerald O., Wang C., Wu J., Hsu M-A., Menon S., Fallon L., Kanik KS.